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Abstract
Recurrence and second primary cancer (SPC) continue to represent major obstacles to long-term survival in head and neck
cancer (HNC). Our aim was to evaluate whether established demographics, lifestyle-related risk factors for HNC and
clinical data are associated with recurrence and SPC in HNC. We conducted a multicentre study by using data from five
studies members of the International Head and Neck Cancer Epidemiology consortium—Milan, Rome, Western Europe,
Sao Paulo, and Japan, totalling 4005 HNC cases with a median age of 59 (interquartile range 52–67). Multivariate hazard
ratios (HRs) and 95% confidence intervals (CIs) were estimated for recurrence and SPC. During follow-up, 1161 (29%)
patients had recurrence and 343 (8.6%) developed SPC. Advanced tumour stage was associated with increased risk of
recurrence in HNC overall (HR = 1.76, 95% CI 1.41–2.19). Women with laryngeal cancer had a reduced risk of recurrence
compared to men (HR = 0.39, 95% CI: 0.24–0.74). Concerning predictors of SPC, advanced age (HR = 1.02; 95% CI:
1.00–1.04) and alcohol consumption ([ 1 drink per day, HR = 2.11; 95% CI: 1.13–3.94) increased the risk of SPC among
patients with laryngeal cancer. Additionally, women were at higher risk of SPC, in HNC overall group (HR = 1.68; 95%
CI: 1.13–2.51) and oropharyngeal cancer group (HR = 1.74; 95% CI: 1.02–2.98). Tumour stage and male gender (larynx
only) were positive predictors of cancer recurrence in HNC patients. Predictors of SPC were advanced age and alcohol use
among laryngeal cancer cases, and female gender for oropharyngeal and HNC overall.
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Introduction
Head and neck cancer (HNC) is the sixth most common
cancer in men and the 13th in women worldwide, with
195,000 new cases estimated in the South-East Asia
Region, 148,000 in the European Region and 101,000 in
the Region of the Americas in 2012. These regions account
for about three-fourths of worldwide HNC cases [1].
Following diagnosis of HNC, 5-year relative survival var-
ies substantially across countries [2–4]. In Europe, five-
year age-standardised relative survival is the highest for
laryngeal cancer and the poorest for hypopharyngeal can-
cer: 59% for larynx, 45% for oral cavity, 39% for
oropharynx, and 25% for hypopharynx. For those surviving
the first year, the 5-year conditional survival probability
increases to 71% for larynx, 62% for oral cavity, 58% for
oropharynx and 41% for hypopharynx [3].
Recurrent disease and second primary cancer (SPC)
continue to represent the major obstacles to long-term sur-
vival in HNC [6, 7]. Despite advances in the treatment of
HNC, it is currently well established that the percentage of
patients who will develop recurrent disease can be as high as
50% [8]. HNC survivors also have an increased risk of
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developing SPC compared to the overall population, with
frequent SPC of the head and neck, oesophagus, and lung,
which are tobacco- and alcohol-related cancers [6]. The
incidence of SPC varies substantially across several studies,
depending mainly on the follow-up time and systematic
screening of patients with HNC [6]. A multicentre study
from 13 population-based cancer registries in Europe,
Canada, Australia, and Singapore, including 99,257 patients
who were diagnosed with a first HNC between 1943 and
2000 found a proportion of SPC development of 10.9% [9].
So far, a few large studies evaluated whether established
demographics and lifestyle-related risk factors for HNC
influence recurrence, and development of SPC in HNC
patients. To explore these issues, we conducted a multi-
centre study by using data from studies conducted in
Brazil, Italy, and Japan, which are members of the Inter-
national Head and Neck Cancer Epidemiology
(INHANCE) Consortium, totalling 4005 HNC cases.
Methods
Study population
We included patients 18 years and older with histologically
confirmed primary squamous cell carcinoma of the head
and neck arising in the four major anatomical sites of the
oral cavity, oropharynx, hypopharynx, and larynx. Patients
with primary cancers outside these four anatomical sites,
patients with a history of previous cancers, and with
incomplete data or follow-up were excluded. Participants
were selected from five referent studies within the
INHANCE Consortium [10]: Milan (Italy), Rome (Italy),
Western Europe involving three Italian centres [Aviano
(Friuli Venezia Giulia), Padua (Veneto), Turin (Pie-
monte)], Sao Paulo (Brazil), and Nagoya (Japan).
The study was approved by the local Ethical Commit-
tees at each participating centre and written informed
consents were obtained from all study subjects. The
recruitment period started in 2001 for Nagoya, 2002 for
Aviano, Milan, Padua, Rome, and Sao Paulo, and ended in
2005 for Aviano, Padua, Turin and Japan, 2009 for Milan,
and 2014 for Rome and Sao Paulo. A total of 4005 eligible
subjects were included in the analysis of recurrence, while
3982 subjects were considered for the analysis of SPC.
Data collection
Patients were interviewed face-to-face in all centres by trained
interviewers or medical doctors using a structured and vali-
dated questionnaire. All patients were evaluated for gender,
age, ethnicity, education level, site of primary tumour,
tumour, node, metastasis (TNM) stage, treatment
characteristics, comorbidity and smoking and alcohol con-
sumption. Information on alcohol and smoking habits con-
sidered the time period ending 1 year prior to HNC diagnosis.
These data were pooled and managed by the INHANCE
consortium coordinator. Data on tumour pathology, treatment
characteristics, cancer recurrence and SPC were obtained
from medical records and cancer registries. Different study
centres used different cancer codes, which were converted
into International Classification of Diseases for Oncology
(ICD-O-2) when included into this study.
All cases of first primary HNCs were followed up for
cancer recurrence and/or SPC from the date of initial head
and neck cancer diagnosis to the date of event, end of
follow-up, or loss to follow-up, whichever occurred first.
Death certificate data were used to track the cause of death
which was coded according to the ICD, Ninth Revision. All
the data from participating centres were collected by the
project team at the Universita` Cattolica del Sacro Cuore in
Rome and were cleaned and checked for internal consis-
tency. Clarifications were requested from the original
investigators when needed.
Study variables and outcomes definition
HNCs were classified according to the following anatomic
sites using the ICD-O-2 codes: oral cavity (C00.3–C00.9,
C02.0–C02.3, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8,
C04.9, C05.0, C06.0–C06.2, C06.8, and C06.9), orophar-
ynx (C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8,
C09.9, C10.0–C10.4, C10.8, and C10.9), hypopharynx
(C12.9, C13.0–C13.2, C13.8, and C13.9), oral cavity or
pharynx overlapping or not otherwise specified (C02.8,
C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8), larynx
(codes C32.0–C32.3 and C32.8–C32.9). Cancers were
staged according to the TNM Staging System [11]. Index
cancer stage was then dichotomized into early stage (in-
cluding I and II clinical stage) and late stage (III and IV).
We also clustered treatment into five categories: surgery
only; surgery with radiation; radiation and/or chemother-
apy; surgery plus radiation and/or chemotherapy; and
other. Education data were classified into three strata:
college graduate, high-technical school graduate and less
than high school depending on the level of formal educa-
tion of participants. Patients were categorized as never,
former, or current smokers or missing in case that the
information was not available. Cumulative tobacco con-
sumption was calculated as intensity of smoking (never
smokers, 20 or less cigarettes/day, [ 20 cigarettes/day),
and smoking duration in years (never smokers, B 20,
[ 20 years). Regarding the alcohol drinking status, sub-
jects were classified as never, former and current drinkers,
and according to the intensity of use as never drinkers,
those who had B 1 drink equivalent/day, and those with
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[ 1 drinks/day. Former users were defined as those who
quit cigarette smoking or alcohol consumption for 1 or
more years prior to the tumour diagnosis.
Cancer recurrence was defined as local, regional or
distant return of cancer of the same histologic type, usually
after a period of time during which the cancer could not be
detected and after that the patient was defined as disease
free. SPC was defined by the criteria of Warren and Gates
[12] in the Italian participating centres, where second
tumour had to be different in histopathologic type, or in
case of the same type to be clearly separated by more than
2 cm of normal epithelium, or occurring more than 3 years
after the treatment for the primary tumour. In the Japanese
study, SPC was defined as a metachronous invasive solid
cancer developing C 6 months after an index HNC. If the
second cancer was of different histopathologic type, or if it
developed in a different location, it was coded as a SPC. If
the second cancer was histopathologically the same and
developed in the same region as the index cancer, it was
only coded as a SPC if greater than 60 months had passed
since the index diagnosis. The Brazilian study considered
SPC as a new tumour diagnosed after a primary, in another
location and confirmed by anatomical exam. In all partic-
ipating studies, SPC was needed to be pathologically
confirmed as distinct malignancy, with the possibility of
metastatic tumour being excluded.
Statistical analysis
Descriptive analyses were conducted to describe the study
population by demographic and known HNC risk factors.
The survival after initial tumour development was set as
the time interval from the diagnosis of the index tumour to
most recent follow-up or the patient’s death. The survival
rate was calculated with the Kaplan–Meier method, which
was also used to plot the survival curves.
The impact of predictor variables on cancer recurrence
and development of SPC was determined using univariate
and multivariate analyses. In the initial univariate analyses,
epidemiological variables included age in years, ethnicity,
sex, body mass index (BMI), education, and smoking and
alcohol status, while clinical characteristics included
tumour site, stage, and presence of comorbidity. A multi-
variable proportional hazards model was set up by
including the variables that reported a prognostic potential
in the univariate analysis (p\ 0.1). The Cox’s proportional
hazards model was used to determine independent predic-
tors of cancer recurrence and SPC. We used Schoenfeld
residuals to formally test the Cox proportional hazards
assumption for each covariate [13]. Analyses were per-
formed for overall HNC and for separate subsite (oral
cavity, oropharynx, hypopharynx and larynx) where pos-
sible, and statistical significance was set at p\ 0.05. We
also restricted our study population for the SPC analyses, to
the patients with follow-up of at least two years, since it
has been reported that the interval between the index and
the second tumour ranges from 2 to 4 years [14, 15]. All
statistical analyses were performed using Stata software
(StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP).
Results
We included a total of 4005 HNC cases in the recurrence
analysis and 3982 cases in the SPC analysis from five
studies within the INHANCE consortium (Table 1). The
majority of the patients were from Brazil, both for the
recurrence (70.7%) and the SPC (70.8%) analysis, then
from Italy–Rome, Milan, Aviano, Padua and Turin (21.9%
for the recurrence, and 21.8% for SPC), and finally from
Japan (7.3 and 7.4% of the cases in recurrence and SPC
analyses, respectively).
The recurrence analysis included 1351 (36.0%) patients
with oral cavity cancer, 1249 (33.3%) laryngeal cancer,
799 (21.3%) oropharyngeal cancer, 356 (9.5%) hypopha-
ryngeal cancer, and 250 (6.2%) patients with oral cavity or
pharynx not otherwise specified cancer. SPC analysis
included 1340 (35.9%) patients with oral cavity cancer,
1244 (33.3%) laryngeal cancer, 795 (21.3%) oropharyngeal
cancer, 356 (9.5%) hypopharyngeal cancer and the rest of
the patients (6.2%) with oral cavity or pharynx not other-
wise specified cancer. Median follow up time for cases
included in the recurrence analysis was 21 (IQR 9–55)
months, ranged from 17 (IQR 8–40) months in Sao Paulo
to 88 (IQR 53–99) months in Aviano. During the follow-
up, 1161 (29.0%) patients had cancer recurrence. When
looking at the location of primary cancer, during the fol-
low-up 117 (32.9%) hypopharyngeal cancer patients had a
recurrence, 423 (31.3%) oral cancer patients, 244 (30.5%)
oropharyngeal cancer patients, 296 (23.7%) laryngeal
cancer patients and 81 (32.4%) oral cavity or pharynx not
otherwise specified cancer cases.
Regarding the 3982 patients included in SPC analysis,
median follow-up time was 26 (IQR 11–59) months, from
20 (IQR 10–44) months in the Sao Paulo study to 82 (IQR
31–98) months in Aviano, during which 343 (8.6%)
patients developed an SPC. Around 10% of patients with
primary laryngeal cancer had SPC, 8.1% of patients with
oral cavity cancer, 7.7 and 7.6% with oropharynx and
hypopharynx cancer, respectively, and 8.5% of patients
with oral cavity or pharynx not otherwise specified cancer
developed an SPC (Table 2).
When considering all HNC sites, recurrence-free 5-year
survival was 5.90% (standard deviation (SD) = 0.24): oral
cavity 6.95% (SD = 0.25), oropharynx 7.30% (SD = 0.26),
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hypopharynx 3.92% (SD = 0.2), and larynx 4.8% (SD =
0.21) (Fig. 1). On the other hand, SPC-free 5-year survival
was 5.97% (SD = 0.24) for all HNC combined, 8.56%
(SD = 0.28) for oral cavity, 5.92% (SD = 0.24) orophar-
ynx, 4.92% (SD = 0.22) for hypopharynx and 4.25%
(SD = 0.20) for laryngeal cancer (Figure not shown). We
further explored the differences in survival by cancer type
and for the analysis of the second primary no survival
curve was statistically different from the others, while for
the recurrence analysis only larynx cancer had a statisti-
cally greater survival (p\ 0.001).
Predictors of the cancer recurrence
Distributions of the selected covariates and adjusted HRs
for cancer recurrence by tumour site and considering HNC
overall are presented in Table 3. Median age of patients
included in the analysis was 59 years (IQR 52–67) with
higher prevalence of males (77.8%), Caucasians (71.9%),
normal BMI (57.8%) and low education level (less than
high-school, 80.3%). Females with laryngeal cancer had a
reduced risk of cancer recurrence (HR = 0.39, 95% CI
0.24–0.74). Tumour stage IV was associated with an
increased risk of recurrence in HNC overall (HR = 1.76,
95% CI 1.41–2.19), oral cavity cancer patients (HR = 1.85,
95% CI 1.31–2.61), and oropharyngeal cancer (HR = 2.56,
95% CI 1.19–5.51), while tumour stage III showed to have
higher risk of recurrence only in HNC overall (HR = 1.29,
95% CI 1.00–1.67). Exploring the lifestyle habits in detail,
we found that patients with oral cavity cancer that were
former alcohol consumers had a lower risk of cancer
recurrence (HR = 0.64, 95% CI 0.44–0.95) while current
consumers with hypopharyngeal cancer had an increased
risk (HR = 3.43; 95% CI 1.05–11.26). No further signifi-
cant association was reported for alcohol drinking and
smoking habits.
Predictors of the second primary cancer
There were 3081 (77.6%) men and 889 (22.4%) women
included in the SPC analysis, with a median age at diag-
nosis of 59 (IQR, 52–67) years, predominantly Caucasians
(71.9%), normal BMI (57.7%) and with low educational
level (less than high school, 80.3%). Table 4 presents
Table 1 Characteristics of head and neck cancer cases from 5 studies participating in the international head and neck cancer epidemiology
(INHANCE) Consortium, according to tumour site
INHANCE studies Recruitment period Oral cavity Oropharynx Hypopharynx Larynx OC, OP, HP NOS Total
n %a n %a n %a n %a n % n %b
4005 cases included in recurrence analysis
Milan, Italy 2002–2009 19 16.2 7 6.0 7 6.0 84 71.8 3 2.5 120 3.0
Rome, Italy 2002–2014 79 18.5 73 17.1 18 4.2 256 60.1 5 1.2 431 10.8
Western Europe
Aviano 2002–2005 40 38.1 32 30.5 8 7.6 25 23.8 2 1.9 107 2.7
Padua 2002–2005 24 22.0 24 22.0 14 12.8 47 43.1 1 0.9 110 2.7
Turin 2003–2005 47 43.9 22 20.6 7 6.5 31 29.0 3 2.7 110 2.7
Sao Paulo, Brazil 2002–2014 995 38.3 592 22.8 255 9.8 755 29.1 236 8.3 2833 70.7
Japan 2001–2005 147 50.0 49 16.7 47 16.0 51 17.3 0 0.0 294 7.3
Total 1351 36.0 799 21.3 356 9.5 1249 33.3 250 6.2 4005 100.0
3982 cases included in second primary cancer analysis
Milan, Italy 2002–2009 19 16.2 7 6.0 7 6.0 84 71.8 3 2.5 120 3.0
Rome, Italy 2002–2014 76 18.4 72 17.4 20 4.8 246 59.4 4 1.0 418 10.5
Western Europe
Aviano 2002–2005 42 37.8 34 30.6 9 8.1 26 23.4 2 1.8 113 2.8
Padua 2002–2005 25 21.7 25 21.7 14 12.2 51 44.3 1 0.9 116 2.9
Turin 2003–2005 44 43.6 21 20.8 5 5.0 31 30.7 2 1.9 103 2.6
Sao Paulo, Brazil 2002–2014 987 38.2 587 22.7 254 9.8 755 29.2 235 8.3 2818 70.8
Japan 2001–2005 147 50.0 49 16.7 47 16.0 51 17.3 0 nc 294 7.4
Total 1340 35.9 795 21.3 356 9.5 1244 33.3 247 6.2 3982 100.0
OC oral cavity, OP oropharynx, HP hypopharynx, NOS not otherwise specified, nc not computable
aErcentages were calculated excluding OC, OP, HP NOS
bColumn percentages
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distribution for the selected covariates and adjusted HRs
for SPC by different HNC sites and combined. Female
gender was found to increase the risk of developing SPC
for those with oropharyngeal cancer (HR = 1.74; 95% CI:
1.02–2.98) and HNC overall (HR = 1.68; 95% CI:
1.13–2.51). Advanced age also increased the risk of SPC
development for patients with laryngeal cancer (HR =
1.02; 95% CI: 1.00–1.04). We found lower risk of
developing SPC for Asian ethnic group for those with
hypopharyngeal (HR = 0.12; 95% CI 0.02–0.91) and
laryngeal cancer (HR = 0.04; 95% CI 0.01–0.38). Associ-
ation was not found for the lifestyle-related risk factors,
except the higher risk for those with laryngeal cancer that
consumed more than one drink per day (HR = 2.11; 95%
CI: 1.13–3.94).
Exploring the same predictors but considering the
specific location of SPC (HNC, lung or other) indepen-
dently from the type of primary HNC, we included a total
of 4021 patients with HNC into this analysis, of whom 113
(32.8%) had HN SPC, 54 (15.7%) had lung SPC and 82
(23.8%) had an SPC in other location, while 95 (27.6%)
had no information of SPC site location (Table 5). Analysis
also included 39 patients with missing information on
primary HNC site, of whom one patient had SPC. They
were not considered for the SPC analysis reported in
Table 4. Female gender was associated with higher risk of
developing a HN SPC (HR = 1.54; 95% CI 1.01–2.35), as
well as lung SPC (HR = 4.29; 95% CI 2.24–8.23) and
other location SPC (HR = 1.88; 95% CI: 1.13–3.13). Eth-
nicity and education were found to be associated with
lower risk of SPC. We found lower risk for college/high
school graduate (HR = 0.59; 95% CI 0.39–0.82) when all
cancer sites were combined. Further lower risk for the
development of HN SPC was reported for those college/
high school graduates (HR = 0.49; 95% CI 0.27–0.91), as
well as for patients with Asian ethnicity for the develop-
ment of other location SPC (HR = 0.11; 95% CI
Table 2 Median survival time and number of cancer recurrences and second primary cancer by tumour site and study
Cases included in recurrence analysis (n = 4005) Cases included in second primary cancer analysis (n = 3982)
n Follow-up time (months) Recurrence n Follow-up time (months) Second primary cancer
Median 1Q 3Q n % Median 1Q 3Q n %
Tumour site
Oral cavity 1351 19 8 50 423 31.3 1340 24 12 55 108 8.1
Oropharynx 799 15 7 40 244 30.5 795 18 9 50 61 7.7
Hypopharynx 356 15 7 34 117 32.9 356 20 10 46 27 7.6
Larynx 1249 30 12 66 296 23.7 1244 37 15 69 126 10.1
OC, OP, HP NOS 250 21 7 63 81 32.4 247 25 10 64 21 8.5
INHANCE studies
Milan, Italy 120 50 17 77 20 16.7 120 49 17 79 21 17.5
Rome, Italy 431 27 10 63 169 39.2 418 45 17 82 53 12.7
Western Europe
Aviano 107 88 53 99 21 19.6 113 82 31 98 23 20.4
Padua 110 35 12 96 49 44.5 116 28 8 92 43 37.1
Turin 110 53 11 96 41 37.3 103 60 15 99 18 17.5
Sao Paulo, Brazil 2833 17 8 40 767 27.1 2818 20 10 44 172 6.1
Japan 294 51 14 69 94 32.0 294 59 36 74 13 4.4
Total 4005 21 9 55 1161 29.0 3982 26 11 59 343 8.6
1Q first quartile, 3Q third quartile, OC oral cavity, OP oropharynx, HP hypopharynx, NOS not otherwise specified
Fig. 1 Kaplan–Meier unadjusted recurrence-free 5-year survival by
head and neck cancer site
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Table 5 Multivariate predictors of second primary specific cancer site among 4021 head and neck cancer (HNC) cases
Subjectsa,b Second primary cancer All second primary cancer
sites combinedf,g n = 344
HNCc n = 113 Lungd n = 54 Othere n = 82
n % HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Demographics
Age at diagnosis 4008 59 (52–67)h 1.00 0.98–1.02 1.01 0.98–1.04 1.00 0.98–1.02 1.01 1.00–1.02
Missing 13 0.3
Gender
Men 3111 77.6 1.00 1.00 1.00 1.00
Women 898 22.4 1.54 1.01–2.35 4.29 2.24–8.23 1.88 1.13–3.13 1.11 0.82–1.51
Missing 12 0.3
BMI
Underweight 194 6.7 1.00 1.00 1.00 1.00
Normal range 1676 57.6 0.67 0.27–1.71 0.84 0.11–6.57 0.50 0.15–1.70 0.79 0.40–1.58
Overweight 794 27.3 0.46 0.16–1.29 0.91 0.11–7.81 0.52 0.14–1.89 0.65 0.32–1.35
Obese 245 8.4 0.65 0.20–2.14 0.56 0.03–9.02 0.47 0.09–2.34 0.46 0.18–1.13
Missing 1112 27.7
Ethnicity
Caucasian 2846 72.0 1.00 1.00 1.00 1.00
Black 236 6.0 0.74 0.27–2.04 nc nc 0.28 0.04–2.05 0.47 0.21–1.06
Asian 316 8.0 nc nc nc nc 0.11 0.01–0.78 1.48 0.36–6.06
Other 556 14.1 1.00 0.57–1.78 0.37 0.09–1.54 0.52 0.20–1.30 0.63 0.39–1.01
Missing 67 1.7
Education
Less than high school 2665 80.3 1.00 1.00 1.00 1.00
College/high school graduate 653 19.7 0.49 0.27–0.91 0.52 0.22–1.23 0.70 0.38–1.28 0.59 0.39–0.82
Missing 703 17.5
Tumour characteristics
Stage
I–II 933 28.2 1.00 1.00 1.00 1.00
III–IV 2374 71.8 1.02 0.65–1.61 1.46 0.71–3.02 0.99 0.57–1.72 1.30 0.98–1.74
Missing 714 17.8
Comorbidity
No 440 52.4 1.00 1.00 1.00 1.00
Yes 400 47.6 0.98 0.46–2.09 3.68 1.04–13.02 1.06 0.52–2.13 1.14 0.75–1.73
Missing 3181 79.1
Cigarette smoking
Smoking status
Never 392 10.0 1.00 1.00 1.00 1.00
Former 964 24.5 1.23 0.58–2.62 0.77 0.21–2.74 0.53 0.25–1.14 1.05 0.66–1.68
Current 2574 65.5 1.46 0.72–2.94 2.43 0.82–7.72 0.75 0.38–1.47 1.57 1.01–2.44
Missing 91 2.3
Years of smoking
Never smokers 392 10.2 1.00 1.00 1.00 1.00
B 20 387 10.1 0.98 0.39–2.45 nc nc 0.32 0.11–1.02 0.88 0.49–1.59
[ 20 3057 79.7 1.49 0.75–2.97 2.20 0.75–6.75 0.73 0.38–1.42 1.44 0.94–2.21
Missing 185 4.6
Cigarettes per day
Never smokers 392 10.2 1.00 1.00 1.00 1.00
B 20 2439 63.5 1.32 0.66–2.66 1.56 0.52–4.69 0.69 0.36–1.36 1.28 0.83–1.98
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0.01–0.78). Presence of comorbidity was associated with a
higher risk of lung SPC (HR = 3.68; 95% CI 1.04–13.02).
Alcohol drinking was found to be associated with an
increased risk of developing a HN SPC (former drinking
status, HR = 3.87; 95% CI 1.78–8.44; current drinking
status, HR = 2.24; 95% CI 1.06–4.74; B 1 drinks per day,
HR = 6.64, 95% CI 2.37–18.62; [ 1 drinks per day
HR = 5.78, 95% CI 1.94–17.25), lung SPC ([ 1 drinks per
day, HR = 3.38, 95% CI 1.29–8.84), and also for other
SPC (B 1 drinks per day, HR = 2.47, 95% CI 1.00–6.11;
[ 1 drinks per day HR = 2.88, 95% CI 1.21–6.87). On the
other hand, only current smokers had an increased risk of
SPC when all SPC sites were combined (HR = 1.57; 95%
CI 1.01–2.44) (Table 5).
We also calculated the HRs for the development of SPC
after restricting the sample to patients with follow up of at
least two years, and found that age was associated with an
increased risk of SPC in oral cavity HNC (HR = 1.02, 95%
CI 1.00–1.05), drinking status increased the risk in laryn-
geal cancer (former drinking status, HR = 2.82, 95% CI
1.10–7.23) and all HNC sites combined (HR = 2.08, 95%
CI 1.13–3.85). The amount of alcohol consumed was
associated with the higher risk of developing SPC in HNC
(B 1 drinks per day, HR = 3.02, 95% CI 1.27–7.12; [ 1
drinks per day, HR = 2.76, 95% CI 1.10–6.92) (data not
shown).
Discussion
In this large multicentre study, we evaluated the prognostic
significance of demographic, lifestyle, and clinical char-
acteristics on recurrence and occurrence of SPC. With a
median follow-up of 2 years, recurrences occurred in 29%
of the study patients, while SPCs in 9%, with the majority
in the HNC region followed by cancers of lung. The inci-
dence of recurrences was associated to the primary tumour
staging in patients with oral cavity and oropharyngeal
cancers. Compared to men, female patients with laryngeal
cancer appeared to have a reduced risk of cancer
Table 5 (continued)
Subjectsa,b Second primary cancer All second primary cancer
sites combinedf,g n = 344
HNCc n = 113 Lungd n = 54 Othere n = 82
n % HR 95% CI HR 95% CI HR 95% CI HR 95% CI
[ 20 1011 26.3 1.57 0.74–3.31 2.59 0.83–8.12 0.62 0.29–1.32 1.58 1.00–2.50
Missing 179 4.5
Alcohol drinking
Drinking status
Never drinkers 558 14.1 1.00 1.00 1.00 1.00
Former 1004 25.4 3.87 1.78–8.44 1.87 0.41–8.46 2.05 0.59–7.11 1.67 0.89–3.14
Current 2383 60.4 2.24 1.06–4.74 1.63 0.36–7.30 2.12 0.62–7.28 1.65 0.89–3.06
Missing 76 1.9
Drinks per day
Never drinkers 558 15.1 1.00 1.00 1.00 1.00
B 1 2255 61.2 6.64 2.37–18.62 2.42 0.86–6.85 2.47 1.00–6.11 1.51 1.00–2.29
[ 1 872 23.7 5.78 1.94–17.25 3.38 1.29–8.84 2.88 1.21–6.87 1.37 0.89–2.10
Missing 336 8.4
Text in bold indicates statistically significant risk factors
CI confidence interval, HNC head and neck cancer, HR hazard ratio, nc not computable
aNumber of subject and percentages is referred to all HNC sites together
bTotal number of subject includes 39 patients with missing information on HNC site
cHR adjusted by age at diagnosis, gender and alcohol drinking status
dHR adjusted by age at diagnosis, gender and number of drinks per day
eHR adjusted by age at diagnosis, gender, ethnicity and number of drinks per day
fHR adjusted by age at diagnosis, gender, education level, ethnicity, number of drinks per day and study centre
gTotal second primary cancer include 95 patients with missing information on second primary cancer site
hMedian, interquartile range
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recurrence. With respect to SPCs, female patients with
oropharyngeal cancers appeared to have a higher risk than
males. Advanced age and high alcohol consumption were
risk factor for SPC among patients with laryngeal cancer,
while belonging to the Asian ethnic group was protective.
High tumour stage was associated with higher risk of
recurrence among patients with oral cavity and oropha-
ryngeal cancers, which is in agreement with other studies
[16, 17]. In addition, former alcohol consummation was
associated with lower risk of recurrence in patients with
oral cavity cancer, which is not in line with our previous
study [7], conducted on a smaller sample of patients with
cancer recurrence. In this study, we did not investigate
established factors associated with recurrence, such as
human papillomavirus (HPV) status, and diet [17] because
information on these variables was not available. A recent
large study examined the prognostic utility of HPV
biomarkers among head and neck squamous cell carcinoma
cancer across different global regions, using centralized
testing and controlling for other risk factors [18]. Tumour
p16 and HPV16 DNA positivity were strong biomarkers
for improved survival among oropharyngeal squamous cell
cancer, but their prognostic utility was not as clear among
non-oropharyngeal head and neck squamous cell carci-
noma cancer.
Several epidemiologic studies have examined the asso-
ciation between lifestyle habits such as smoking tobacco
and consuming alcohol, and SPC in patients with HNC
[19, 20]. In our study alcohol, but not tobacco, was a sig-
nificant risk factor for SPC development. These results are
in line with the large body of evidence regarding alcohol
intake and SPC risk in patients with HNC. Our previous
multicentre study conducted in Italy on 117 HNC patients
with SPC reported no significant association for smoking
habits, though the risk for developing SPC increased with
the increasing years of smoking ([ 40) [7]. Subjects from
this study were also included in our current analyses [7]. In
a recent study including nearly 1000 patients who were
treated only in single hospital in South Korea, the reported
risk factors for SPC in head and neck squamous-cell car-
cinoma patients included the index alcohol consumption
other than tumour site and patient age [21]. Our results are
also consistent with those from a large study in 5 centres
from South Europe, which reported a strong association
between alcohol consumption and the risk of developing a
SPC of the upper aerodigestive tract (UADT) among male
patients with laryngeal or hypopharyngeal carcinoma [22].
A systematic review and meta-analysis of existing data
from observational studies on the strength of the associa-
tion of alcohol drinking with SPC risk in patients with
UADT reported an increased risk of UADT SPCs, UADT
and lung cancers, and for any SPCs [20]. Moreover, two
studies investigated the association between SPC and
continued alcohol consumption after UADT tumour diag-
nosis, reporting not consistent results [23, 24]. However,
since information on alcohol consumption after diagnosis
is unknown, it was not possible to investigate this associ-
ation in our study. Smoking is the most important risk
factor for developing HNC [25, 26]. Thus, it may seem
surprising that it does not increase the risk of SPC after
HNC as well. We hypothesize that some of the subjects
with primary HNC might have stopped using tobacco after
diagnosis of the first primary tumour, resulting in a
decrease in the risk of tobacco-related SPCs [27]. There is
another consideration. Patients who continue smoking after
cancer diagnosis experience a consistent increase in risk of
death compared with cancer patients who do not smoke
after a cancer diagnosis [28], while persistent alcohol use
did not affect survival [29].
The most obvious strength of this study was the large
number of participants, which included HNC patients from
three continents. Due to the large sample size, we were able
to evaluate the risk of recurrence or recurrence by HNC
subsites adjusting for multiple factors. Another strength is
the detailed information about intensity and duration of
pre-diagnosis tobacco and alcohol use. Limitations in our
study are the lack of information on HPV status when
exploring the recurrence of patients with oropharyngeal
cancer since the risk of recurrence is lower in HPV-related
than HPV-unrelated oropharyngeal squamous cell cancer
[18]. Moreover, we did not have data on lifestyle changes
after cancer diagnosis over time, which may have affected
the prognosis. It was also not possible to investigate the
influence of the persistence of tobacco and alcohol use in
the appearance of SPC. Lastly, short follow-up period is
another limitation, as one participating study had a median
follow-up time lower than 2 years, though approximately
35 to 55% of patients with HNC use to experience
locoregional recurrence or distant metastasis within 2 years
of initial diagnosis [8, 30, 31].
In summary, this large epidemiologic study investigated
the association between demographics and lifestyle-related
risk factors for HNC with recurrence and SPC development
in HNC patients across continents. Tumour stage (both for
oral cavity and oropharynx) and male gender (larynx only)
were positive predictors of cancer recurrence in HNC
patients. Predictors of SPC were advanced age, Asian
ethnicity and alcohol among laryngeal cancer cases, and
female gender for oropharyngeal and HNC overall. It
would be important to collect information on tobacco use,
alcohol consumption, diet habits, and other exposures in
the interval between the first tumour and the occurrence of
recurrence or SPC, to better define their role in reducing
cancer recurrence or SPCs.
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